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Selectiveserotoninreuptakeinhibitors(SSRIs)areincreasinglyprescribedduringpregnancy.Thepurposeofthepresentpaperisto
summarize and evaluate the current evidence for the risk/beneﬁt analysis of SSRI use in human pregnancy. The literature has been
inconsistent. Although most studies have not shown an increase in the overall risk of major malformations, several studies have
suggested that SSRIs may be associated with a small increased risk for cardiovascular malformations. Others have noted associa-
tions between SSRIs and speciﬁc types of rare major malformations. In some studies, there appears to be a small increased risk for
miscarriages, which may be associated with the underlying maternal condition. Neonatal eﬀects have been described in up to 30%
ofneonatesexposedtoSSRIslateinpregnancy.Persistentpulmonaryhypertensionofthenewbornhasalsobeendescribedwithan
absolute risk of < 1%. The risk associated with treatment discontinuation, for example, higher frequency of relapse and increased
risk of preterm delivery, should also be considered. The overall beneﬁt of treatment seems to outweigh the potential risks.
1.Introduction
Selective serotonin reuptake inhibitors (SSRIs) are widely
prescribedforthetreatmentofdepression,anxiety,andother
disorders. Estimates suggest that the lifetime risk for depres-
sion ranges between 10 and 25% with a peak prevalence oc-
curring at childbearing age [1]. According to Evans et al.,
9–14% of all pregnant women display signs of depression
and/orhaveillnessesthatfulﬁlresearchdiagnosticcriteriafor
depression [2]. The prevalence rates of depression during
pregnancy are 7.4%, 12.8%, and 12.0%, for the ﬁrst, second,
and third trimesters, respectively [3]. A number of SSRIs
were introduced since the 1980s, including ﬂuoxetine, ﬂuvo-
xamine,paroxetine,sertraline,citalopram,andescitalopram.
They have better eﬃcacy, tolerability, and safety compared to
ﬁrst-generation antidepressants, for example, tricyclic anti-
depressants,andaresaferinoverdose.Theyexerttheireﬀects
by inhibiting the presynaptic plasma membrane serotonin
transporter.Theserotonintransportermediatesthereuptake
of serotonin into the presynaptic terminal; neuronal uptake
is the primary process by which neurotransmission via
5-hydroxytryptamine (neuronal serotonin) is terminated.
Thus, treatment with an SSRI initially blocks reuptake and
results in enhanced and prolonged serotonergic neurotrans-
mission. All SSRIs share a similar mechanism of action des-
pite having diﬀerent chemical structures. The use of antide-
pressants and anxiolytics has shifted from the domain of
psychiatry to primary care, with the discovery of more selec-
tiveandsaferdrugs.SSRIuseinpregnancyhasincreasedover
theyears[4–7].Inrecentyearstheproportion ofpregnancies
with SSRI exposure in the USA is 6% [6, 7]. SSRIs readily
cross the human placenta [8, 9]. In spite of the widespread
useofSSRIsduringpregnancyandtherelativeextensiveliter-
ature available, there are conﬂicting views on the safety of
these drugs during pregnancy. The purpose of the present
traditional literature review is to summarize and evaluate the
current evidence for the risk beneﬁt analysis of SSRI use in
human pregnancy.
2. HumanStudieson SSRIsinPregnancy
2.1. Congenital Anomalies (see Table 1). A summary of stud-
ies on the use of SSRIs in human pregnancy is presented in2 Obstetrics and Gynecology International
Table 1. Many studies on the use of SSRIs during pregnancy
have not shown an increase in the overall risk of major mal-
formations [10–28]. Several studies have suggested that the
use of SSRIs, particularly paroxetine, may be associated with
a small increased risk for cardiovascular malformations [29–
38]. Other studies have noted associations between SSRIs
in pregnancy and speciﬁc types of relatively rare major mal-
formations (neural tube defects, craniosynostosis, omphalo-
cele,orrightventricularoutﬂowtractdefects)[39–41].Some
of these studies are retrospective and burdened with recall
and selection bias. The largest dataset with prospective expo-
sure information available to date is from the Swedish Medi-
cal Birth Registry. Their initial report has been negative [16].
Later, increased risk of cardiovascular defects was observed
with paroxetine, predominantly of septal defects [30, 31].
Recently, new associations were noted, for cystic kidney with
SSRIs, for relatively severe malformations with ﬂuoxetine,
and for any cardiovascular defect and hypospadias with
paroxetine [38]. Three recently published meta-analyses on
paroxetine exposure in pregnancy and cardiovascular mal-
formations have not been consistent [42–44]. In the meta-
analysispublishedbyBar-Ozetal.[42],ﬁrsttrimesterparox-
etine exposure was associated with a signiﬁcant increase in
the risk of cardiac anomalies. Women using antidepressants
in pregnancy were more likely to utilize ultrasound in preg-
nancy and postnatal echocardiograms compared with
women who did not. In this study, signiﬁcantly more women
receivingparoxetineusedthemedicationforanxietyorpanic
disorders compared to women using other SSRIs. Detection
bias was suggested as a contributing factor to the observed
risk of cardiovascular malformations with paroxetine. In the
meta-analysis published by O’Brien et al. [43], no increased
risk of congenital malformations was associated with parox-
etine. Cardiac malformation rates were similar and within
population norms. In the meta-analysis published by Wurst
et al. [44], there was an increased risk for combined cardiac
defects and aggregated congenital defects with ﬁrst trimester
paroxetine use. Two opposing commentaries on this topic
wererecentlypublished[45,46].Thedeﬁnitionofcardiovas-
cular malformations varied among studies, some including
small septal defects, while others excluded them. The incon-
sistency across these studies may be explained by diﬀerences
in study design, by confounding factors, for example, mater-
nal underlying psychiatric disorder, coadministered medica-
tions, lifestyle factors (smoking, drinking), maternal BMI,
and diabetes, or they may be spurious. Overall, there are over
33,000 reported pregnancy outcomes after prenatal exposure
to various SSRIs.
We have calculated the overall rate of major congenital
anomalies and of cardiovascular anomalies in the published
prospective studies after prenatal exposure to SSRIs, where
rates were available [10–15, 20, 25, 32, 33]a n df o u n d3 . 8 %
(189/4920) and 0.9% (53/6094), respectively, both well
within their baseline risk in the general population. It can
be summarized that the majority of the prospective studies
have not shown an increase in the overall risk of major mal-
formations.ThestudieswhichhavesuggestedthatSSRIsmay
be associated with a small increased risk for malformations
were particularly with paroxetine.
2.2. Judging the Evidence for SSRIs as Possible Causes of Major
Malformations. Seven criteria for proof of human terato-
genicityhavebeenamalgamatedbyShepard[51]andarepre-
sented in Table 2 and discussed as follows.
(1) ManyofthestudieswithpositiveﬁndingsonSSRIsin
pregnancy are prescription studies, and women may
not have actually taken the drugs. Exact timing of
exposure during sensitive periods is often problem-
atic, although exposure preceded the outcome.
(2) There are several isolated studies with inconsistent
ﬁndings of statistically signiﬁcant associations. Con-
founding factors are often insuﬃciently controlled
for. Many of the prospective studies are underpow-
ered for associations between exposure and speciﬁc
malformations. Many of the retrospective studies are
burdened with potential biases. All studies consid-
ered here are observational. The relative risk even in
positive studies is below six and the lower bound of
the 95% conﬁdence interval often close to one. The
ﬁndings in regard to the type of malformations are
inconsistent in the underlying studies and even in
studies from the same database published at diﬀerent
time points.
(3) In the positive studies, there was some dominance of
cardiovascular malformations, septal defects in some
studies, and right ventricular outﬂow tract obstruc-
tion defects in others. In the case of SSRIs, particu-
larly paroxetine; however, they were non-speciﬁc. In
manyofthelargestudies,diagnosisofmalformations
uses classiﬁcation codes and lacks careful delineation
of clinical cases.
(4) The fourth criterion is not relevant in the context of
SSRIs. SSRIs are common exposures in pregnancy,
and most of the described defects are also relatively
common.
(5) Animal reproductive studies in rats and rabbits ad-
ministered paroxetine [52], ﬂuoxetine [53], or sertra-
line [54] during organogenesis did not show a terato-
genic eﬀect.
(6) There is evidence based on mouse whole-embryo
studies to suggest that serotonin plays a role in car-
diovascular and craniofacial development [55–58].
Paroxetine 1μM was shown to decrease serotonin-
mediated proliferation of dissociated rat embryonic
cardiac myocytes [59]. Rat whole-embryo culture re-
sults showed an increase in branchial bar fusion, but
not cardiac malformations, after exposure to parox-
etine at concentrations much higher than those
achieved clinically [60]. It has been speculated that
the observed malformations in vitro may be early
ontogenetic indicators for infrequent cardiovascular
anomalies observed in vivo. Fluoxetine was found to
adversely aﬀect cell viability and diﬀerentiation to
cardiomyocytes at higher concentrations than those
achievedclinicallyinadose-dependentmannerusing
mouseembryonicstemcellsystem[61].SSRIsinhibitObstetrics and Gynecology International 3
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P
a
r
o
x
e
t
i
n
e
b
y
1
/
3
N
o
i
n
c
r
e
a
s
e
i
n
t
h
e
r
i
s
k
o
f
b
i
r
t
h
d
e
f
e
c
t
s
P
r
e
s
c
r
i
p
t
i
o
n
s
t
u
d
y
S
c
h
l
o
e
m
p
e
t
a
l
.
,
[
2
2
]
P
r
o
s
p
e
c
t
i
v
e
c
o
m
p
a
r
a
t
i
v
e
c
o
h
o
r
t
n
=
1
1
9
P
a
r
o
x
e
t
i
n
e
N
o
i
n
c
r
e
a
s
e
i
n
t
h
e
r
i
s
k
o
f
b
i
r
t
h
d
e
f
e
c
t
s
U
n
p
u
b
l
i
s
h
e
d
d
a
t
a
V
i
a
l
e
t
a
l
.
,
[
2
3
]
P
r
o
s
p
e
c
t
i
v
e
c
o
m
p
a
r
a
t
i
v
e
c
o
h
o
r
t
n
=
6
8
3
P
a
r
o
x
e
t
i
n
e
N
o
i
n
c
r
e
a
s
e
i
n
t
h
e
r
i
s
k
o
f
b
i
r
t
h
d
e
f
e
c
t
s
U
n
p
u
b
l
i
s
h
e
d
d
a
t
a
K
¨
a
l
l
´
e
n
a
n
d
O
t
t
e
r
b
l
a
d
-
O
l
a
u
s
s
o
n
,
a
[
3
0
]
,
a
[
3
1
]
S
w
e
d
i
s
h
M
e
d
i
c
a
l
B
i
r
t
h
R
e
g
i
s
t
e
r
,
u
p
d
a
t
e
d
S
S
R
I
s
:
n
=
6
5
5
5
F
l
u
o
x
e
t
i
n
e
n
=
9
2
6
C
i
t
a
l
o
p
r
a
m
n
=
2
7
0
1
P
a
r
o
x
e
t
i
n
e
n
=
9
5
9
S
e
r
t
r
a
l
i
n
e
n
=
1
9
0
6
F
l
u
v
o
x
a
m
i
n
e
n
=
3
8
E
s
c
i
t
a
l
o
p
r
a
m
n
=
7
2
I
n
c
r
e
a
s
e
d
r
i
s
k
o
f
c
a
r
d
i
o
v
a
s
c
u
l
a
r
d
e
f
e
c
t
s
w
i
t
h
p
a
r
o
x
e
t
i
n
e
O
R
1
.
6
3
9
5
%
C
I
1
.
0
5
–
2
.
5
3
m
o
s
t
l
y
s
e
p
t
a
l
d
e
f
e
c
t
s
1
3
/
2
0
I
n
c
o
m
p
l
e
t
e
d
r
u
g
r
e
p
o
r
t
i
n
g
,
p
o
t
e
n
t
i
a
l
d
e
t
e
c
t
i
o
n
b
i
a
s
,
m
u
l
t
i
p
l
e
c
o
m
p
a
r
i
s
o
n
s
D
a
v
i
s
e
t
a
l
.
,
[
2
4
]
R
e
t
r
o
s
p
e
c
t
i
v
e
c
a
s
e
c
o
n
t
r
o
l
s
t
u
d
y
S
S
R
I
s
:
n
=
8
0
5
P
a
r
o
x
e
t
i
n
e
n
=
1
8
2
N
o
i
n
c
r
e
a
s
e
i
n
t
h
e
r
i
s
k
o
f
b
i
r
t
h
d
e
f
e
c
t
s
P
r
e
s
c
r
i
p
t
i
o
n
s
t
u
d
y
B
´
e
r
a
r
d
e
t
a
l
.
,
[
4
8
]
R
e
t
r
o
s
p
e
c
t
i
v
e
n
e
s
t
e
d
c
a
s
e
-
c
o
n
t
r
o
l
s
t
u
d
y
n
=
1
4
0
3
a
n
t
i
d
e
p
r
e
s
s
a
n
t
s
P
a
r
o
x
e
t
i
n
e
n
=
5
4
2
n
(
>
2
5
m
g
/
d
)
=
1
4
3
o
t
h
e
r
S
S
R
I
s
n
=
4
4
3
N
o
i
n
c
r
e
a
s
e
i
n
t
h
e
r
a
t
e
o
f
c
o
n
g
e
n
i
t
a
l
a
n
o
m
a
l
i
e
s
,
i
n
c
r
e
a
s
e
d
r
i
s
k
f
o
r
o
v
e
r
a
l
l
a
n
d
c
a
r
d
i
a
c
m
a
l
f
o
r
m
a
t
i
o
n
s
i
n
t
h
e
h
i
g
h
-
d
o
s
e
(
>
2
5
m
g
/
d
)
g
r
o
u
p
(
A
d
O
R
3
.
0
7
(
9
5
%
C
I
1
.
0
0
–
9
.
4
2
)
)
P
r
e
s
c
r
i
p
t
i
o
n
s
t
u
d
y
,
c
a
l
c
u
l
a
t
i
o
n
o
f
a
v
e
r
a
g
e
d
a
i
l
y
d
o
s
e
a
ﬀ
e
c
t
e
d
b
y
d
u
r
a
t
i
o
n
i
n
t
h
e
ﬁ
r
s
t
t
r
i
m
e
s
t
e
r
A
l
w
a
n
e
t
a
l
.
,
[
3
9
]
R
e
t
r
o
s
p
e
c
t
i
v
e
c
a
s
e
-
c
o
n
t
r
o
l
s
t
u
d
y
C
a
s
e
s
:
n
=
9
6
2
2
C
o
n
t
r
o
l
:
s
n
=
4
0
9
2
S
S
R
I
s
2
.
4
%
o
f
c
a
s
e
s
2
.
1
%
o
f
c
o
n
t
r
o
l
s
,
(
s
e
r
t
r
a
l
i
n
e
0
.
8
%
,
ﬂ
u
o
x
e
t
i
n
e
0
.
7
%
,
p
a
r
o
x
e
t
i
n
e
0
.
5
%
c
i
t
a
l
o
p
r
a
m
0
.
2
%
)
A
s
s
o
c
i
a
t
i
o
n
s
b
e
t
w
e
e
n
a
n
y
S
S
R
I
a
n
d
c
r
a
n
i
o
s
y
n
o
s
t
o
s
i
s
,
p
a
r
o
x
e
t
i
n
e
/
s
e
r
t
r
a
l
i
n
e
a
n
d
a
n
e
n
c
e
p
h
a
l
y
,
p
a
r
o
x
e
t
i
n
e
a
n
d
r
i
g
h
t
v
e
n
t
r
i
c
u
l
a
r
o
u
t
ﬂ
o
w
t
r
a
c
t
o
b
s
t
r
u
c
t
i
o
n
d
e
f
e
c
t
s
,
o
m
p
h
a
l
o
c
e
l
e
a
n
d
g
a
s
t
r
o
s
c
h
i
s
i
s
—
s
m
a
l
l
a
b
s
o
l
u
t
e
r
i
s
k
s
S
m
a
l
l
n
u
m
b
e
r
s
o
f
e
x
p
o
s
e
d
i
n
f
a
n
t
s
f
o
r
i
n
d
i
v
i
d
u
a
l
a
n
o
m
a
l
i
e
s
,
m
u
l
t
i
p
l
e
c
o
m
p
a
r
i
s
o
n
s
,
d
a
t
a
o
n
d
o
s
a
g
e
u
n
a
v
a
i
l
a
b
l
e
,
p
o
t
e
n
t
i
a
l
r
e
c
a
l
l
a
n
d
s
e
l
e
c
t
i
o
n
b
i
a
s
e
sObstetrics and Gynecology International 5
T
a
b
l
e
1
:
C
o
n
t
i
n
u
e
d
.
S
t
u
d
y
D
e
s
i
g
n
S
a
m
p
l
e
s
i
z
e
S
S
R
I
R
e
s
u
l
t
s
C
o
m
m
e
n
t
s
G
S
K
/
C
o
l
e
e
t
a
l
.
,
[
4
9
,
5
0
]
R
e
t
r
o
s
p
e
c
t
i
v
e
e
p
i
d
e
m
i
o
l
o
g
i
c
s
t
u
d
y
n
=
4
9
3
6
a
n
t
i
d
e
p
r
e
s
s
a
n
t
s
P
a
r
o
x
e
t
i
n
e
n
=
1
0
2
0
I
n
c
r
e
a
s
e
d
r
i
s
k
f
o
r
o
v
e
r
a
l
l
c
o
n
g
e
n
i
t
a
l
a
n
o
m
a
l
i
e
s
f
o
r
p
a
r
o
x
e
t
i
n
e
(
A
d
O
R
1
.
8
9
(
9
5
%
C
I
1
.
2
0
–
2
.
9
8
)
)
M
a
n
u
f
a
c
t
u
r
e
r
s
’
d
a
t
a
f
r
o
m
a
l
a
r
g
e
U
S
i
n
s
u
r
e
r
u
s
i
n
g
d
a
t
a
o
r
i
g
i
n
a
l
l
y
f
o
r
a
s
t
u
d
y
o
n
b
u
p
r
o
p
i
o
n
i
n
p
r
e
g
n
a
n
c
y
L
o
u
i
k
e
t
a
l
.
,
[
4
0
]
R
e
t
r
o
s
p
e
c
t
i
v
e
c
a
s
e
-
c
o
n
t
r
o
l
s
t
u
d
y
9
8
4
9
i
n
f
a
n
t
s
w
i
t
h
d
e
f
e
c
t
s
a
n
d
5
8
6
0
w
i
t
h
o
u
t
S
S
R
I
s
:
2
.
7
%
o
f
i
n
f
a
n
t
s
w
i
t
h
o
u
t
m
a
l
f
o
r
m
a
t
i
o
n
s
,
1
.
6
–
4
.
8
%
o
f
i
n
f
a
n
t
s
w
i
t
h
v
a
r
i
o
u
s
m
a
l
f
o
r
m
a
t
i
o
n
s
A
s
s
o
c
i
a
t
i
o
n
b
e
t
w
e
e
n
p
a
r
o
x
e
t
i
n
e
a
n
d
r
i
g
h
t
v
e
n
t
r
i
c
u
l
a
r
o
u
t
ﬂ
o
w
t
r
a
c
t
o
b
s
t
r
u
c
t
i
o
n
d
e
f
e
c
t
s
,
c
l
u
b
f
o
o
t
,
u
n
d
e
s
c
e
n
d
e
d
t
e
s
t
e
s
a
n
d
N
T
D
s
,
s
e
r
t
r
a
l
i
n
e
a
n
d
o
m
p
h
a
l
o
c
e
l
e
a
n
d
s
e
p
t
a
l
d
e
f
e
c
t
s
—
s
m
a
l
l
a
b
s
o
l
u
t
e
r
i
s
k
s
S
m
a
l
l
n
u
m
b
e
r
o
f
e
x
p
o
s
e
d
i
n
f
a
n
t
s
f
o
r
i
n
d
i
v
i
d
u
a
l
a
n
o
m
a
l
i
e
s
,
m
u
l
t
i
p
l
e
c
o
m
p
a
r
i
s
o
n
s
,
d
a
t
a
o
n
d
o
s
a
g
e
u
n
a
v
a
i
l
a
b
l
e
,
p
o
t
e
n
t
i
a
l
r
e
c
a
l
l
a
n
d
s
e
l
e
c
t
i
o
n
b
i
a
s
e
s
E
i
n
a
r
s
o
n
e
t
a
l
.
,
[
2
5
]
P
r
o
s
p
e
c
t
i
v
e
c
o
m
p
a
r
a
t
i
v
e
c
o
h
o
r
t
s
t
u
d
y
8
T
I
S
e
s
n
=
1
1
7
4
P
a
r
o
x
e
t
i
n
e
N
o
i
n
c
r
e
a
s
e
i
n
t
h
e
r
i
s
k
o
f
c
a
r
d
i
a
c
d
e
f
e
c
t
s
i
n
t
h
e
p
a
r
o
x
e
t
i
n
e
g
r
o
u
p
(
0
.
7
%
)
c
o
m
p
a
r
e
d
t
o
c
o
n
t
r
o
l
s
S
p
o
n
t
a
n
e
o
u
s
l
y
r
e
s
o
l
v
e
d
c
a
r
d
i
o
v
a
s
c
u
l
a
r
d
e
f
e
c
t
s
n
o
t
i
n
c
l
u
d
e
d
D
i
a
v
-
C
i
t
r
i
n
e
t
a
l
.
,
[
3
2
]
P
r
o
s
p
e
c
t
i
v
e
c
o
m
p
a
r
a
t
i
v
e
c
o
h
o
r
t
s
t
u
d
y
3
T
I
S
e
s
S
S
R
I
:
n
=
8
0
9
1
4
6
7
c
o
n
t
r
o
l
s
P
a
r
o
x
e
t
i
n
e
n
=
3
4
8
F
l
u
o
x
e
t
i
n
e
n
=
2
5
3
I
n
c
r
e
a
s
e
d
C
r
O
R
f
o
r
c
a
r
d
i
o
v
a
s
c
u
l
a
r
a
n
o
m
a
l
i
e
s
a
f
t
e
r
p
a
r
o
x
e
t
i
n
e
3
.
4
7
(
9
5
%
C
I
1
.
1
3
–
1
0
.
5
8
)
A
d
O
R
2
.
6
6
(
9
5
%
C
I
0
.
8
0
–
8
.
9
0
)
,
C
r
O
R
4
.
8
1
(
9
5
%
C
I
1
.
5
6
–
1
4
.
7
1
)
A
d
O
R
4
.
4
7
(
9
5
%
C
I
1
.
3
1
–
1
5
.
2
7
)
a
f
t
e
r
ﬂ
u
o
x
e
t
i
n
e
A
f
t
e
r
a
d
j
u
s
t
m
e
n
t
f
o
r
p
o
t
e
n
t
i
a
l
c
o
n
f
o
u
n
d
e
r
s
O
R
s
i
g
n
i
ﬁ
c
a
n
t
o
n
l
y
f
o
r
ﬂ
u
o
x
e
t
i
n
e
a
n
d
c
i
g
a
r
e
t
t
e
s
m
o
k
i
n
g
o
f
1
0
o
r
m
o
r
e
/
d
a
y
,
s
e
p
t
a
l
d
e
f
e
c
t
s
c
o
n
s
i
d
e
r
e
d
m
a
j
o
r
a
n
o
m
a
l
i
e
s
e
v
e
n
w
h
e
n
s
p
o
n
t
a
n
e
o
u
s
l
y
c
l
o
s
e
d
,
l
a
r
g
e
c
o
n
ﬁ
d
e
n
c
e
i
n
t
e
r
v
a
l
s
O
b
e
r
l
a
n
d
e
r
e
t
a
l
.
,
[
3
3
]
P
o
p
u
l
a
t
i
o
n
-
b
a
s
e
d
c
o
h
o
r
t
s
t
u
d
y
,
C
a
n
a
d
a
,
B
C
S
R
I
s
:
n
=
2
6
2
5
S
R
I
s
+
B
Z
:
n
=
9
6
8
C
o
n
t
r
o
l
s
:
n
=
1
0
7
,
3
2
0
S
R
I
s
:
n
=
2
6
2
5
S
R
I
s
+
B
Z
:
n
=
9
6
8
c
o
n
t
r
o
l
s
:
n
=
1
0
7
,
3
2
0
I
n
c
r
e
a
s
e
d
r
i
s
k
o
f
c
a
r
d
i
o
v
a
s
c
u
l
a
r
(
C
V
)
d
e
f
e
c
t
s
a
f
t
e
r
c
o
m
b
i
n
e
d
e
x
p
o
s
u
r
e
t
o
S
R
I
a
n
d
B
Z
,
i
n
c
r
e
a
s
e
d
r
i
s
k
f
o
r
a
n
A
S
D
a
f
t
e
r
S
R
I
m
o
n
o
t
h
e
r
a
p
y
,
m
a
j
o
r
a
n
o
m
a
l
i
e
s
a
f
t
e
r
ﬂ
u
o
x
e
t
i
n
e
a
n
d
B
Z
C
l
i
n
i
c
a
l
s
i
g
n
i
ﬁ
c
a
n
c
e
o
f
t
h
e
a
n
o
m
a
l
y
n
o
t
v
e
r
i
ﬁ
e
d
,
m
a
n
y
s
e
p
t
a
l
d
e
f
e
c
t
s
m
i
n
o
r
a
n
d
s
p
o
n
t
a
n
e
o
u
s
l
y
r
e
s
o
l
v
e
,
a
t
t
e
m
p
t
t
o
c
o
n
t
r
o
l
f
o
r
c
o
n
f
o
u
n
d
e
r
s
P
e
d
e
r
s
e
n
e
t
a
l
.
,
b
[
3
4
]
P
o
p
u
l
a
t
i
o
n
-
b
a
s
e
d
c
o
h
o
r
t
s
t
u
d
y
,
D
a
n
i
s
h
r
e
g
i
s
t
r
i
e
s
S
S
R
I
s
:
n
=
1
3
7
0
4
9
3
,
1
1
3
c
o
n
t
r
o
l
s
F
l
u
o
x
e
t
i
n
e
n
=
3
4
8
C
i
t
a
l
o
p
r
a
m
n
=
4
6
0
P
a
r
o
x
e
t
i
n
e
n
=
2
9
9
S
e
r
t
r
a
l
i
n
e
n
=
2
5
9
>
1
S
S
R
I
n
=
1
9
3
I
n
c
r
e
a
s
e
d
p
r
e
v
a
l
e
n
c
e
o
f
s
e
p
t
a
l
d
e
f
e
c
t
s
w
i
t
h
s
e
r
t
r
a
l
i
n
e
(
O
R
3
.
2
5
(
9
5
%
C
I
1
.
2
1
–
8
.
7
5
)
)
a
n
d
c
i
t
a
l
o
p
r
a
m
(
O
R
2
.
5
2
(
9
5
%
C
I
1
.
0
4
–
6
.
1
0
)
)
P
r
e
s
c
r
i
p
t
i
o
n
s
t
u
d
y
,
p
o
t
e
n
t
i
a
l
s
e
l
e
c
t
i
o
n
b
i
a
s
,
u
n
d
e
r
l
y
i
n
g
c
o
n
d
i
t
i
o
n
p
o
t
e
n
t
i
a
l
c
o
n
f
o
u
n
d
e
r
,
i
n
f
o
r
m
a
t
i
o
n
o
n
m
a
l
f
o
r
m
a
t
i
o
n
f
r
o
m
h
o
s
p
i
t
a
l
r
e
g
i
s
t
r
y
(
m
o
r
e
s
e
n
s
i
t
i
v
e
t
o
s
e
v
e
r
e
a
n
d
v
i
s
i
b
l
e
m
a
l
f
o
r
m
a
t
i
o
n
s
)
W
i
c
h
m
a
n
e
t
a
l
.
,
[
2
6
]
R
e
t
r
o
s
p
e
c
t
i
v
e
c
o
n
t
r
o
l
l
e
d
r
e
v
i
e
w
o
f
m
e
d
i
c
a
l
r
e
c
o
r
d
s
a
t
t
h
e
M
a
y
o
C
l
i
n
i
c
S
S
R
I
s
:
n
=
8
0
8
2
4
,
4
0
6
c
o
n
t
r
o
l
s
C
i
t
a
l
o
p
r
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Table 2: Shepard’s amalgamation of criteria for proof of human teratogenicity (Source: shepard, 1994 [51]) applied to SSRIs.
Criterion Fulﬁllment by SSRIs
(1) Proven exposure to agent at critical time(s) in prenatal development. No
(2) Consistent ﬁndings by two or more epidemiologic studies of high quality:
(a) Control of confounding factors
(b) Suﬃcient numbers
(c) Exclusion of positive or negative bias factors No
(d) Prospective studies, if possible
(e) Relative risk of six or more (?)
(3) Careful delineation of the clinical cases. A speciﬁc defect or syndrome, if present, is very
helpful No
(4) Rare environmental exposure associated with rare defect Not applicable
(5) Teratogenicity in experimental animals No
(6) The association should make biological sense No
(7) Proof in an experimental system that the agent acts in an unaltered state Evidence of placental transfer
Note: items (1), (2), and (3) or (1), (3), and (4) are essential criteria. Items (5), (6), and (7) are helpful but not essential.
the serotonin transporter. However, developmental
defects were not observed in mutant serotonin trans-
porter knockout mice [62]. In another study, gross
morphologic abnormalities were not seen in sero-
tonintransporterknockout mice,butassociationwas
found with sudden death of the newborn mice in the
ﬁrst week after delivery [63]. Histologic analysis of
heart sections of these mice showed that they develop
cardiac ﬁbrosis. In terms of biological plausibility, in
vitro studies have been helpful in suggesting mech-
anistic information that adds to the plausibility of
the suspected association, though in concentrations
much higher than plasma concentrations in humans
in clinical settings. However, as stated earlier, in
vivo animal studies to date have not supported an
association between in utero exposure to SSRIs and
major anomalies.
(7) There is evidence for placental transfer of SSRIs.
In summary, despite some troubling associations bet-
ween SSRIs and major malformations, especially cardiovas-
cular, the overall current scientiﬁc evidence has not fulﬁlled
the criteria for proof of human teratogenicity of SSRIs. Des-
pite having over 33,000 reported pregnancy outcomes after
prenatal exposure to various SSRIs, the diﬀerences in the
design of these studies and their conﬂicting results are con-
fusing.One,therefore,wonderswhetherfurtherwell-design-
ed epidemiologic studies, with suﬃcient power and good
control of potential confounders will be helpful in verifying
whether SSRIs are indeed associated with a small increased
teratogenic risk, especially regarding cardiovascular anoma-
lies. In our opinion, the current data do not support tera-
togenicity of SSRIs.
2.3. Miscarriage, Intrauterine Growth Restriction (IUGR), and
Preterm Delivery. Most studies did not speciﬁcally focus
on the impact of SSRIs on the risk of miscarriage. It was
often a secondary outcome without observing a signiﬁcantly
increased risk. There was an increase in the miscarriage risk
in two meta-analyses [64, 65]. However, in the included pro-
spective cohort studies, crude rates were reported, and the
eﬀect of earlier gestational age at contact, which is an impor-
tant factor [66], was not corrected for. In two studies that
speciﬁcally focused on the risk of miscarriage, an increased
risk was found with the use of antidepressants during preg-
nancy [67, 68], SSRIs alone, serotonin-norepinephrine reup-
take inhibitors alone, and combined use of antidepressants
[68]. When looking at antidepressant use by type, paroxetine
alone and venlafaxine alone were associated with increased
miscarriage risk. Despite an attempt to adjust for psychiatric
history, the possibility of confounding by underlying psychi-
atric disorder could not be ruled out.
In a Finnish study, there was no increase in the rate of
preterm delivery, SGA or LBW [19]. The risk of both low
birth weight and preterm delivery was increased in infants
who were born to mothers who had received SSRI therapy
[17, 21]. Infants exposed to SSRIs had shorter gestation and
lower birth weight compared to nonexposed infants [69].
The increased risk of low birth weight remained signiﬁcant,
even when maternal illness severity was accounted for. The
adjusted OR for preterm delivery was doubled in SSRI-
exposed women compared to two groups of women who
had not used SSRIs during pregnancy, one with psychiatric
history and another without [70]. In another study, the risk
of preterm delivery was not signiﬁcantly increased among
SSRI users, but the risk of SGA oﬀspring was increased
among women who continued SSRI use beyond the ﬁrst
trimester [71]. In a study from the Quebec Pregnancy Regis-
try, no association was found between SSRIs and the risk of
SGA regardless of trimester of exposure [72]. In other stud-
ies, there was an increased risk for preterm delivery among
women exposed to SSRIs in the second or third trimesters
[38] or to antidepressants [73] with no increased risk for
LBWor SGA.Theunderlying psychiatric disorder isapoten-
tial confounder in most of these studies.8 Obstetrics and Gynecology International
In summary, associations were found in some studies
between the use of SSRIs during pregnancy and risk of mis-
carriage,IUGR,orpretermdelivery.Mostofthesestudiesare
potentially confounded by the gestational age at initial con-
tact and the underlying psychiatric disorder.
2.4. Neonatal Eﬀects. Neonatal symptoms have been describ-
edinitiallyfollowingprenatalexposuretoﬂuoxetine[74]and
later on after exposure to paroxetine and other SSRIs [75–
81]. Neonatal toxicity or discontinuation (withdrawal, absti-
nence) syndromes associated with SSRIs are characterized
by irritability, abnormal crying, tremor, and poor neonatal
adaptation including respiratory distress, tachypnoea, jitter-
iness, lethargy, poor tone or colour, and, rarely, convulsions.
The neonatal eﬀects have been described in up to 30% of
neonates exposed to SSRIs late in pregnancy [82]. Most sym-
ptoms are mild and transient.
It can be concluded that SSRI use late in pregnancy, simi-
lar to many other psychotropic drugs, is associated with neo-
natal transient eﬀects.
2.5. Persistent Pulmonary Hypertension of the Newborn.
Some epidemiologic studies have suggested an association
between maternal use of SSRIs late in pregnancy and an
increased risk of persistent pulmonary hypertension of the
newborn (PPHN) [38, 83, 84]. In these studies the absolute
risk of PPHN was <1%. In the study which used data from
the Swedish Medical Birth Register [84], the eleven infants
whose mothers reported the use of SSRI in pregnancy and
had PPHN survived the neonatal period. Contrary to the
above, other studies, possibly underpowered, did not ﬁnd
such an association [26, 85]. A recent study found PPHN to
be associated with mode of delivery, speciﬁcally caesarean
delivery prior to the onset of labour, but not with SSRI use
in the second half of pregnancy [86].
Insummary,anabsoluteriskof<1%forPPHNininfants
exposed to SSRIs cannot be excluded, although studies are
not consistent.
2.6. Neurodevelopmental Eﬀects. Most studies have focused
on possible postnatal neurodevelopmental eﬀects. Children
of mothers exposed in pregnancy to ﬂuoxetine or tricyclic
antidepressants were neurodevelopmentally assessed and
compared to an unexposed control group. Similar global IQ
and language scores were found in the three groups [87, 88].
No signiﬁcant diﬀerences in neurobehavioral scores were
found between children whose mothers were taking ﬂuoxe-
tine during pregnancy and nonexposed children [89]. Nor-
mal development was observed in a small group of children
exposed in pregnancy to citalopram and followed up to 1
year [90]. Infant developmental assessment done at 2 and
8 months of age revealed no signiﬁcant diﬀerences between
SSRI-exposedandunexposedinfants[91].Levelsofinternal-
izing or externalizing behaviours did not signiﬁcantly diﬀer
betweenchildrenprenatallyexposedtoSSRIsandunexposed
[92,93].Ontheotherhand,maternaldepressionandanxiety
were associated with increased reports of internalizing and
externalizing behaviours in their children.
Mental developmental indexes were similar in children
whose mothers were diagnosed with major depressive dis-
order treated or untreated in pregnancy. However, children
exposed to SSRIs scored lower on the psychomotor develop-
mental indexes and the motor quality factor of the behavi-
oural rating scale compared to unexposed children [94]. In
a follow-up study using a psychomotor developmental test
(Boel), abnormal test was more frequent in children pre-
natally exposed to antidepressants compared to unexposed
[95]. In another neurobehavioral assessment study, new-
borns prenatally exposed to SSRIs had abnormal outcomes
including increased motor activity, fewer changes in behavi-
oural state, and abnormal sleep patterns [96].
Children’s developmental milestones were assessed using
a questionnaire at 6 and 19 months of age. Second or third
trimester exposure to antidepressants was associated with
later gross motor developmental milestones, though still
within normal range, compared to unexposed children [97].
Children who had neonatal abstinence syndrome had
similar mean overall developmental results compared to
those who did not; however, they were more likely to have
abnormal results on the social component of the Denver
developmental test [98].
A recent prospective study demonstrated that SSRIs
during pregnancy aﬀect the neurobehavioral development of
the human fetus [99]. Fetuses exposed to SSRIs exhibited
dose-related increased motor activity and disrupted sleep.
The signiﬁcance of the observed changes on postnatal
development is unclear.
In a recent population-based case-control study, a two-
fold increased risk of autism spectrum disorders was found
with prenatal exposure to SSRIs [100]. Further studies are
needed to verify the suggested association.
In summary, in most of the studies that focused on the
possible neurodevelopmental eﬀects of prenatal SSRI ex-
posure, there is no conclusive evidence for an increased risk
of adverse long-term eﬀects.
2.7. Risk of Treatment Discontinuation. When evaluating the
risk/beneﬁt ratio of SSRI treatment in pregnancy, the risks
associated with treatment discontinuation should also be
considered. Abrupt discontinuation of psychotropic drugs
in pregnancy is associated with physical and psychological
adverse eﬀects [101]. SSRI treatment discontinuation during
pregnancy is associated with a higher frequency of relapse
[102]. Depression is associated with an increased risk for
preterm delivery [103–105]. The risk of preterm delivery in-
creases with increasing severity of depression [106]. Treated
women have lower depressive symptom scores and better
functioning [105]. These risks should be a factor in the deci-
sion making in regard to treatment continuation during pre-
gnancy.
3. Conclusion
Clinicians are faced with the diﬃcult cost-beneﬁt consider-
ation of either making a recommendation to treat or not to
treatmaternaldepressionoranxietywithSSRIsinpregnancy.Obstetrics and Gynecology International 9
In the ﬁeld of teratology, decisions on new medications dur-
ing pregnancy often need to be made with insuﬃcient hu-
man pregnancy experience on their safety. In the case of
SSRIs in pregnancy, despite extensive available studies on
their use, quality is more important than quantity, and data
are still not conclusive.
In summary, most studies on the use of SSRIs during
pregnancy support that they are not major human terato-
gens. A small increased risk for cardiovascular anomalies,
especially with paroxetine, cannot be excluded. There ap-
pearstobeasmallincreasedriskformiscarriages,whichmay
be associated with the underlying maternal condition. Neo-
nates of mothers treated with SSRIs should be closely follow-
ed up after delivery, as there is an increased risk of tran-
sient neonatal eﬀe c t s .T h e r ei sn oc o n c l u s i v ee v i d e n c ef o r
adverse long-term neurodevelopmental eﬀects of prenatal
SSRI exposure. Discontinuation of treatment may pose risks,
for example, higher frequency of relapse and increased risk
of preterm delivery. Hence, the general beneﬁt of treatment
seems to outweigh the potential small risk of untoward
eﬀects on the embryo, fetus, or neonate.
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